
Bioporto A/S
CSE:BIOPOR

Bioporto A/S
Cash Taxes Paid
Bioporto A/S
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Bioporto A/S
CSE:BIOPOR
|
Cash Taxes Paid
-kr5.5m
|
CAGR 3-Years
-132%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
![]() |
Genmab A/S
CSE:GMAB
|
Cash Taxes Paid
kr343m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
![]() |
Zealand Pharma A/S
CSE:ZEAL
|
Cash Taxes Paid
-kr11.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-160%
|
CAGR 10-Years
N/A
|
|
![]() |
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash Taxes Paid
€5.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash Taxes Paid
kr9.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
![]() |
Saniona AB
STO:SANION
|
Cash Taxes Paid
-kr8.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

See Also
What is Bioporto A/S's Cash Taxes Paid?
Cash Taxes Paid
-5.5m
DKK
Based on the financial report for Sep 30, 2024, Bioporto A/S's Cash Taxes Paid amounts to -5.5m DKK.
What is Bioporto A/S's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
-3%
Over the last year, the Cash Taxes Paid growth was 0%. The average annual Cash Taxes Paid growth rates for Bioporto A/S have been -132% over the past three years , -3% over the past five years .